QSAR modeling of the inhibition of reverse transcriptase enzyme with benzimidazolone analogs

Medicinal Chemistry Research

Volumn 20, Issue 9, 2011, Pages 1530-1541

  Kumar, Surendra ^a   Singh, Vineet ^a   Tiwari, Meena ^a  

^a SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Anti HIV agents; Enhanced replacement method; Forward stepwise regression analysis; Genetic function approximation; QSAR

Indexed keywords

BENZIMIDAZOLONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DESIGN; ENHANCED REPLACEMENT METHOD; ENZYME INHIBITION; FORWARD STEPWISE REGRESSION; GENETIC FUNCTION APPROXIMATION; HYDROPHOBICITY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS;

EID: 84856217947     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9406-2     Document Type: Conference Paper

References (46)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr AC 19:716-723
2. Balzarini J, Pelemans H, Aquaro S, Perno CF, Witvrouw M, Schols D, De Clercq E, Karlsson A (1996) Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol 50:394-401 (Pubitemid 26265145)
3. Barreca ML, Rao A, Luca LD, Zappala M, Monforte AM, Maga G, Pannecouque C, Balzarini J, De Clercq E, Chimirri A, Monforte P (2005) Computational strategies in discovering novel nonnucleoside inhibitors of HIV-1 RT. J Med Chem 48:3433-3437 (Pubitemid 40628061)
4. Barreca ML, Rao A, Luca LD, Iraci N, Monforte AM, Maga G, De Clercq E, Pannecouque C, Balzarini J, Chimirri A (2007) Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett 17:1956-1960 (Pubitemid 46367661)
5. Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, Amin DE, Gress J, Hawkins M, Jarosinski P, Moss H (1991) Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. New Engl J Med 324:137-144
6. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356:1423-1430
7. Chemical Computing Group, Inc (2008) Molecular operating environment (MOE2008.10), Montreal, Quebec, Canada. http://www.chemcomp.com
8. De Clercq E (2005a) Emerging anti-HIV drugs. Exp Opin Emerg Drugs 10:241-274 (Pubitemid 40695127)
9. De Clercq E (2005b) New approaches toward ati-HIV chemotherapy. J Med Chem 48:1297-1313 (Pubitemid 40364540)
10. Dournon E, Rozenbaum W, Michon C, Perronne C, De Truchis P, Bouvet E, Levacher M, Matheron S, Gharakhanian S, Girard PM, Salmon D, Leport C, Dazza MC, Regnier B (1988) Effects of Zidovudine in 365 consecutive patients with AIDS or AIDSrelated complex. Lancet 322:1297-1302
11. Draper NR, Smith H (1981) Applied regression analysis. Wiley, New York
12. Duchowicz PR, Fernandez M, Caballero J, Castro EA, Fernandez FM (2006) QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem 14:5876-5889 (Pubitemid 44096998)
13. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Nat Struct Biol 2:303-308
14. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New Engl J Med 317: 185-191 (Pubitemid 17114872)
15. Golbraikh A, Tropsha A (2002) Beware of Q2. J Mol Graph Model 20:269-276
16. Hannongbua S, Pungpol P, Limtrakul J, Wolschann P (1999) Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors. J Comput Aided Mol Des 13:563-577 (Pubitemid 29524913)
17. Hawkins MD, Basak SC, Mills D (2003) Assessing model fit by crossvalidation. J Chem Inf Comput Sci 43:579-586
18. Jalali-Heravi M, Parastar F (2000) Use of artificial neural networks in a QSAR study of anti-hiv activity for a large group of Hept derivatives. J Chem Inf Comput Sci 40:147-154
19. Kleim JP, Bender R, Billhardt UM, Meichsner C, Riess G, Rosner M, Winkler I, Paessens A (1993) Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother 37:1659-1664 (Pubitemid 23226379)
20. Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT (1990) 20, 30-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. New Engl J Med 322:1333-1340 (Pubitemid 20154475)
21. Leonard J, Roy K (2003) QSAR modeling of anti-HIV activities of alkenyldiarylmethanes using topological and physicochemical descriptors. Drug Des Discov 18:165-180 (Pubitemid 39157468)
22. Mandloi D, Joshi S, Khadikar PV, Khosla N (2005) QSAR study on the antibacterial activity of some sulfa drugs: Building blockers of mannich bases. Bioorg Med Chem Lett 15:405-411 (Pubitemid 39647159)
23. Mao C, Subeck EA, Venkatachalam TK, Uckun FM (2000) Structurebased drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem Pharmacol 60:1251
24. Mercader AG, Duchowicz PR, Fernandez FM Castro EA (2008) Modified and enhanced replacement method for the selection of molecular descriptors in QSAR and QSPR studies. Chemom Intell Lab Syst 92:138-144
25. Mitra I, Roy PP, Kar S, Ojha PK, Roy K (2010) On further application of rm 2 as a metric for validation of QSAR models. J Chemometrics 24:22-33
26. Mitsuya H, Yarchoan R, Broder S (1990) Molecular targets for AIDS therapy. Science 249:1533-1544
27. Monforte AM, Rao A, Logoteta P, Ferro S, Luca LD, Barreca ML, Iraci N, Maga G, De Clercq E, Pannecouque C, Chimirri A (2008) Novel N1-substituted 1, 3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem 16:7429-7435
28. Monforte AM, Logoteta P, Stefania F, Luca LD, Iraci N, Maga G, De Clercq E, Pannecouque C, Chimirri A (2009) Design, synthesis, and structure-activity relationships of 1, 3-dihydrobenzimidazol-2-one analogues as anti-HIV agents. Bioorg Med Chem 17: 5962-5967
29. Moore RD, Hidalgo J, Sugland BW, Chaisson RE (1991) Zidovudine and the natural history of the acquired immunodeficiency syndrome. New Engl J Med 324:1412-1416
30. Nanni RG, Ding J, Jacobo-Molina A, Hughes SH, Arnold E (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: Implication for drug design. Perspect Drug Discov Des 1:129-150
31. Opar A (2007) New HIV drug classes on the horizon. Nat Rev Drug Discov 6:258-259 (Pubitemid 46505874)
32. Pogliani L (1994) Structure property relationships of amino acids and some dipeptides. Amino Acids 6:141-153 (Pubitemid 24128747)
33. Ren J, Diprose J, Warren J, Esnouf RM, Bird LE, Ikemizu S, Slater M, Milton J, Balzarini J, Stuart DI, Stammers DK (2000) Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases: Structural and biochemical analyses. J Biol Chem 275:5633-5639 (Pubitemid 30115202)
34. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New Engl J Med 317:192-197 (Pubitemid 17103099)
35. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Shih CK, Mayers M, Griffin J (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 68:1660-1666 (Pubitemid 24065732)
36. Rogers D, Hopfinger AJ (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comput Sci 34:854-866
37. Roy K, Mandal AS (2008) Development of linear and nonlinear predictive QSAR models and their external validation using molecular similarity principle for anti-HIV indolyl aryl sulfones. J Enzyme Inhib Med Chem 23:980-995
38. Roy P, Roy K (2008) On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 27:302-313
39. Roy PP, Paul S, Mitra I, Roy K (2009) On two novel parameters for validation of predictive QSAR models. Molecules 14:1660-1701
40. Schinazi RF, Larder BA, Mellors JW (1997) Mutations in retroviral genes associated with drug resistance. Int Antiviral News 5: 129-135
41. Shen M, Beguin C, Golbraikh A, Stables JP, Kohn H, Tropsha A (2004) Application of predictive QSAR models to database mining: Identification and experimental validation of novel anticonvulsant compounds. J Med Chem 47:2356-2364 (Pubitemid 38478859)
42. Talete SRL (2007) DART-decision analysis by ranking techniques (version 2.0), http://www.talete.mi.it
43. Tropsha A, Gramatica P, Gombar VK (2003) The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 2:69-77 (Pubitemid 36717473)
44. Wold S, Eriksson L (1995) Statistical validation of QSAR results. In: Van de Waterbeemd H (ed) Chemometrics methods in molecular design. VCH, Weinheim, pp 309-318
45. Yarchoan R, Mitsuya H, Myers CE, Broder S (1987) Clinical pharmacology of 30-azido-20, 30-dideoxythymidine (zidovudine) and related dideoxynucleosides. New Engl J Med 321:726-738 (Pubitemid 19239705)
46. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, Emini EA (1995) L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39:2602-2605